Citations

Mayo Clinic

Clear

7716 citation(s) found for "Ma, Daniel".

Functional Assays for Classification ofBRCA2Variants of Uncertain Significance
Farrugia, Daniel J., Agarwal, Mukesh K., Deffenbaugh, Amie M., Pruss, Dmitry, Frye, Cynthia, Wadum, Linda, Johnson, Kiley, Mentlick, Jennifer, Tavtigian, Sean V. , Goldgar, David E., Pankratz, V. Shane , Goldgar, David E., Couch, Fergus J.

Cancer Research | May 2, 2008 | Volume: 68 | Issue: 9 | Pages: 3523-3531

10.1158/0008-5472.can-07-1587 | PMID 18451181 Get It

AbstractThe assessment of the influence of many rare BRCA2 missense mutations on cancer risk has proved difficult. A multifactorial likelihood model that predicts the odds of cancer causality for missense variants is effective, but is limited by the availability of family data. As an alternative, we developed functional assays that measure the influence of missense mutations on the ability of BRCA2 to repair DNA damage by homologous recombination and to control centriole amplification. We evaluated 22 missense mutations from the BRCA2 DNA binding domain (DBD) that were identified in multiple breast cancer families using these assays and compared the results with those from the likelihood model. Thirteen variants inactivated BRCA2 function in at least one assay; two others truncated BRCA2 by aberrant splicing; and seven had no effect on BRCA2 function. Of 10 variants with odds in favor of causality in the likelihood model of 50:1 or more and a posterior probability of pathogenicity of 0.99, eight inactivated BRCA2 function and the other two caused splicing defects. Four variants and four controls displaying odds in favor of neutrality of 50:1 and posterior probabilities of pathogenicity of at least 1 × 10−3 had no effect on function in either assay. The strong correlation between the functional assays and likelihood model data suggests that these functional assays are an excellent method for identifying inactivating missense mutations in the BRCA2 DBD and that the assays may be a useful addition to models that predict the likelihood of cancer in carriers of missense mutations. [Cancer Res 2008;68(9):3523–31]
Comparison of Real-Time PCR for Detection of the tcdC Gene with Four Toxin Immunoassays and Culture in Diagnosis of Clostridium difficile Infection
Sloan, Lynne M., Duresko, Brian J., Gustafson, Daniel R., Rosenblatt, Jon E.

Journal of Clinical Microbiology | April 24, 2008 | Volume: 46 | Issue: 6 | Pages: 1996-2001

10.1128/jcm.00032-08 | PMID 18434563 Get It

ABSTRACT We have developed a rapid real-time PCR method using fluorescence resonance energy transfer probes and the LightCycler (Roche Diagnostics), which will detect the presence of the tcdC gene of Clostridium difficile in stool samples. Our PCR method also will identify the presence of base pair deletions, one of which (18 bp) has been associated with the “epidemic” toxin-hyperproducing strains. We compared the results of this PCR with those of three C. difficile toxin-detecting enzyme immunoassays (EIAs), an EIA for the detection of glutamate dehydrogenase (GDH), and culture of C. difficile . A total of 200 stool specimens were studied by the methods under comparison. C. difficile was isolated from 49 specimens by culture, and 44 of these were confirmed as containing one of the genes associated with toxin production (“toxigenic culture”). Using toxigenic culture as the “gold standard”, the sensitivities, specificities, and positive and negative predictive values, respectively, of the assays were 48%, 98%, 88%, and 87% for the Premier toxin A and B test; 48%, 99%, 91%, and 87% for the ImmunoCard toxin A & B test; 48%, 84%, 46%, and 85% for the Xpect C. difficile toxin A/B test; 32%, 100%, 100%, and 84% for the Triage C. difficile panel (for toxin A); and 86%, 97%, 90%, and 96% for the LightCycler PCR. Thus, in comparison to the sensitivity of toxigenic culture, the sensitivities of the toxin immunoassays were unacceptably low, while the LightCycler real-time PCR assay for the detection of the tcdC gene of C. difficile is sensitive and specific.
Assessing the Measure of a New Drug: Is Survival the Only Thing That Matters?
Sargent, Daniel J. , Hayes, Daniel F. , Sargent, Daniel J

Journal of Clinical Oncology | April 17, 2008 | Volume: 26 | Issue: 12 | Pages: 1922-1923

10.1200/jco.2007.14.8064 | PMID 18421044 Get It

Early Experience with the Bioabsorbable Anal Fistula Plug
Lawes, Daniel, Efron, J., Abbas, Maher A. , Heppell, Jacques, Young‐Fadok, Tonia M.

World Journal of Surgery | March 28, 2008 | Volume: 32 | Issue: 6 | Pages: 1157-1159

10.1007/s00268-008-9504-1 | PMID 18373120 Get It

AbstractPurposeManagement of anal fistula represents a balance between curing the condition and maintaining anal continence. Recent reports of the results of the porcine anal fistula plug have demonstrated excellent fistula healing rates without reporting significant complications.MethodsThe outcome of patients who underwent treatment for anal fistula with the Surgisis® anal plug was retrospectively reviewed.ResultsTwenty patients were treated; three underwent concomitant anal advancement flap at the time of plug placement. Seventeen patients had a trans‐sphincteric fistula, and three had an anoperineal fistula. Ten patients had previously undergone failed surgical therapy to cure their fistula, including anal advancement flap in four, muscle interposition flap in two, fistulotomy in two, and cutting seton placement in two. Mean follow‐up was 7.4 months. Only 4 of 17 (24%) patients treated with the plug alone had closure of their fistula. Acute postoperative sepsis was seen in 5 of 17 (29%) patients treated with the plug alone. Four developed perianal abscesses that required incision and drainage, and one intersphincteric abscess was treated with antibiotics. Two of the patients who underwent concomitant anal advancement flaps and plug placement healed successfully.ConclusionsContrary to other published series, the use of the Surgisis® anal plug was associated with a low rate of fistula healing and a high incidence of perianal sepsis. The addition of a transanal advancement flap to the procedure may improve success rates.
ECG-Gated Cardiac CT Angiography Using 64-MDCT for Detection of Patent Foramen Ovale
Williamson, Eric E. , Kirsch, Jacobo , Araoz, Philip A. , Edmister, Whitney B., Borgeson, Daniel D., Glockner, James F., Breen, Jerome F.

American Journal of Roentgenology | March 20, 2008 | Volume: 190 | Issue: 4 | Pages: 929-933

10.2214/ajr.07.3140 | PMID 18356439 Get It

Human phenylethanolamineN-methyltransferase genetic polymorphisms and exercise-induced epinephrine release
Snyder, Eric M., Salavaggione, Oreste E., Moon, Irene, Batzler, Anthony , Yee, Vivien C., Schaid, Daniel J. , Johnson, Bruce D., Weinshilboum, Richard M. , Ji, Yuan , Fridley, Brooke L. , Joyner, Michael J. , Weinshilboum, Richard M.

Physiological Genomics | March 19, 2008 | Volume: 33 | Issue: 3 | Pages: 323-332

10.1152/physiolgenomics.00248.2007 | PMID 18349382 Get It

Phenylethanolamine N-methyltransferase (PNMT) catalyzes the synthesis of epinephrine from norepinephrine. We previously identified and functionally characterized common sequence variation in the PNMT gene. In the present study, we set out to determine whether common PNMT genetic polymorphisms might be associated with individual variation in circulating epinephrine levels during exercise in 74 Caucasian American subjects. Circulating epinephrine levels were measured in each subject at baseline and during two different levels of exercise, ∼40% and ∼75% of peak workload. The PNMT gene was resequenced with DNA from each study subject. Eight novel PNMT polymorphisms were identified, including a C319T (Arg107Cys) nonsynonymous single nucleotide polymorphism (SNP) and I1G(280)A, a SNP located in the first intron of the gene. The I1G(280)A SNP was significantly associated with decreased exercise-induced circulating epinephrine levels and with a decreased epinephrine-to-norepinephrine ratio. The Cys107 recombinant allozyme displayed significantly lower levels of both PNMT activity and immunoreactive protein than the wild-type allozyme after transfection into COS-1 cells, but it did not appear to be associated with level of epinephrine in these subjects. Electrophoretic mobility shift and reporter gene assays performed with the I1G(280)A SNP indicated that this polymorphism could bind nuclear proteins and might modulate gene transcription. Our studies suggest that functionally significant variant sequence in the human PNMT gene might contribute to individual variation in levels of circulating epinephrine during exercise.
Comparative Bioavailability of Sulindac in Capsule and Tablet Formulations
Mandrekar, Sumithra J. , Carlson, Elsa C., Harmsen, William S. , McGovern, Renee M., Ames, Matthew M. , Boring, Daniel, Network, for the Cancer Prevention, Reid, Joel M. , Green, Erin M. , Szabó, Éva , Limburg, Paul J. , Network, for the Cancer Prevention

Cancer Epidemiology, Biomarkers & Prevention | March 18, 2008 | Volume: 17 | Issue: 3 | Pages: 674-679

10.1158/1055-9965.epi-07-2510 | PMID 18349286 Get It

Abstract The cyclooxygenase (COX)-2 enzyme appears to be an important target for cancer chemoprevention. Given the recent emergence of potentially serious cardiovascular toxicity associated with selective COX-2 inhibitors, nonsteroidal antiinflammatory drugs (NSAIDs), which inhibit both COX-1 and COX-2, have received renewed attention as candidate chemoprevention agents. Sulindac has shown consistent chemopreventive potential in preclinical studies as well as in a limited number of clinical trials reported to date. For the current pharmacokinetic study, sulindac capsules were prepared to facilitate ample agent supplies for future intervention studies. Encapsulation of the parent compound (sulindac sulfoxide) can be readily accomplished, but the effects of alternate formulations on bioavailability have not been rigorously examined. In the present single-dose, two-period crossover trial, we conducted pharmacokinetic analyses of sulindac in capsule (test) versus tablet (reference) formulations. Overall, bioavailability appeared to be higher for the capsule compared with the tablet formulation based on test-to-reference pharmacokinetic variable ratios for the parent compound alone. However, additional analyses based on the sulfide and sulfone metabolites of sulindac with the same pharmacokinetic variables indicated similar chemopreventive exposures between the capsule and tablet formulations. These data support the use of sulindac capsules, which can be readily prepared with matching placebos, in future blinded chemoprevention trials. (Cancer Epidemiol Biomarkers Prev 2008;17(3):674–9)
Targeting NF-κB in Waldenstrom macroglobulinemia
Leleu, Xavier , Eeckhoute, Jérôme , Jia, Xiaoying , Roccaro, Aldo M. , Moreau, Anne-Sophie, Sacco, Antonio , Ngo, Hai T., Runnels, Judith, Melhem, Molly, Burwick, Nicolas, Azab, Abdelkareem, Azab, Feda, Hunter, Zachary R. , Hatjiharissi, Evdoxia , Carrasco, Daniel R., Hideshima, Teru , Brown, Myles , Farag, Mena S. , Treon, Steven P. , Witzig, Thomas E. , Anderson, Kenneth C. , Ghobrial, Irene M. , Roccaro, Aldo M , Hunter, Zachary R , Brown, Myles

Blood | March 12, 2008 | Volume: 111 | Issue: 10 | Pages: 5068-5077

10.1182/blood-2007-09-115170 | PMID 18334673 Get It

Abstract The nuclear factor-κB (NF-κB) path-way has been implicated in tumor B-cell survival, growth, and resistance to therapy. Because tumor cells overcome single-agent antitumor activity, we hypothesized that combination of agents that target differentially NF-κB pathway will induce significant cytotoxicity. Therapeutic agents that target proteasome and Akt pathways should induce significant activity in B-cell malignancies as both pathways impact NF-κB activity. We demonstrated that perifosine and bortezomib both targeted NF-κB through its recruitment to the promoter of its target gene IκB using chromatin immunoprecipitation assay. This combination led to synergistic cytotoxicity in Waldenstrom macroglobulinemia (WM) cells that was mediated through a combined reduction of the PI3K/Akt and ERK signaling pathways, found to be critical for survival of WM cells. Moreover, a combination of these drugs with the CD20 monoclonal antibody rituximab further increased their cytotoxic activity. Thus, effective WM therapy may require combination regimens targeting the NF-κB pathway.
Genome Screen to Detect Linkage to Intracranial Aneurysm Susceptibility Genes
Sauerbeck, Laura, Brown, Robert D., Anderson, Craig S. , Woo, Daniel , Kleindorfer, Dawn , Flaherty, Matthew L. , Deka, Ranjan , Hornung, Richard, Meissner, Irene, Bailey‐Wilson, Joan E. , Connolly, E. Sander , Koller, Daniel L., Investigators, the FIA Study, Derdeyn, Colin P. , Hankey, Graeme J. , Ringer, Andrew J. , Tirschwell, David , Ogilvy, Christopher S. , Foroud, Tatiana , Rouleau, Guy Armand , Lai, Dongbing , Huston, John , Broderick, Joseph P. , Investigators, the FIA Study, Wilson, Richard K , Hankey, Graeme J , Ogilvy, Christopher S , Derdeyn, Colin P

Stroke | March 7, 2008 | Volume: 39 | Issue: 5 | Pages: 1434-1440

10.1161/strokeaha.107.502930 | PMID 18323491 Get It

Background and Purpose— Evidence supports a substantial genetic contribution to the risk of intracranial aneurysm (IA). The purpose of this study was to identify chromosomal regions likely to harbor genes that contribute to the risk of IA. Methods— Multiplex families having at least 2 individuals with “definite” or “probable” IA were ascertained through an international consortium. First-degree relatives of individuals with IA who were at increased risk of an IA because of a history of hypertension or present smoking were offered cerebral magnetic resonance angiography. A genome screen was completed using the Illumina 6K SNP system, and the resulting data from 192 families, containing 1155 genotyped individuals, were analyzed. Narrow and broad disease definitions were used when testing for linkage using multipoint model-independent methods. Ordered subset analysis was performed to test for a gene×smoking (pack-years) interaction. Results— The greatest evidence of linkage was found on chromosomes 4 (LOD=2.5; 156 cM), 7 (LOD=1.7; 183 cM), 8 (LOD=1.9; 70 cM), and 12 (LOD=1.6; 102 cM) using the broad disease definition. Using the average pack-years for the affected individuals in each family, the genes on chromosomes 4 (LOD=3.5; P =0.03), 7 (LOD=4.1; P =0.01) and 12 (LOD=3.6; P =0.02) all appear to be modulated by the degree of smoking in the affected members of the family. On chromosome 8, inclusion of smoking as a covariate did not significantly strengthen the linkage evidence, suggesting no interaction between the loci in this region and smoking. Conclusions— We have detected possible evidence of linkage to 4 chromosomal regions. There is potential evidence for a gene×smoking interaction with 3 of the loci.
Plasma Free Fatty Acid Storage in Subcutaneous and Visceral Adipose Tissue in Postabsorptive Women
Koutsari, Christina , Dumesic, Daniel A. , Patterson, Bruce W. , Votruba, Susanne B. , Jensen, Michael D.

Diabetes | February 20, 2008 | Volume: 57 | Issue: 5 | Pages: 1186-1194

10.2337/db07-0664 | PMID 18285557 Get It

OBJECTIVE— We assessed the direct (VLDL-triglycerides [VLDL-TG] independent) storage of circulating free fatty acids (FFAs) in visceral and subcutaneous fat in postabsorptive women. RESEARCH DESIGN AND METHODS— Twelve women (BMI 29.6 ± 6.6 kg/m2) received an identical, intravenous bolus dose of [1-14C]oleate followed by timed subcutaneous fat biopsies (abdominal and femoral) and then omental fat biopsy during tubal ligation surgery. Regional fat masses were assessed by combining dual-energy X-ray absorptiometry and computed tomography scanning. Separately, we assessed the fraction of FFA tracer entering VLDL-TG over the time representing the delay in collecting omental fat. RESULTS— Site-specific fat specific activity (SA) (dpm/g lipid) decreased as a function of fat mass in both upper-body subcutaneous (UBSQ) and visceral fat depots. These patterns are consistent with dilution of a relatively fixed amount of FFA tracer within progressively greater amounts of fat. Interestingly, femoral SA did not vary as a function of lower-body subcutaneous (LBSQ) fat mass. [1-14C]oleate storage per million LBSQ adipocytes was positively associated with LBSQ fat mass, but no significant relationships were observed in UBSQ or visceral fat depot. The fraction of [1-14C]oleate stored in UBSQ, LBSQ, and visceral fat was 6.7 ± 3.2, 4.9 ± 3.4, and 1.0 ± 0.3%, respectively. Only ∼4% of the tracer traversed VLDL-TG over 9.5 h. CONCLUSIONS— The increase in FFA tracer storage per adipocyte as a function of LBSQ fat mass implies that LBSQ adipocytes, in contrast to UBSQ and omental adipocytes, store more FFA in women with greater adiposity. The direct FFA storage pathway might play a role in favoring lower-body fat accumulation in women.